patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_552225 | REC_0009901 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.6 | 68 | female | 1 | 21 | 3.7 | 7 | osimertinib 80 mg daily | 17.3 | false | MSS | 2026-03-15T05:35:59.307070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276130 | REC_0009902 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.3 | 70 | female | 2 | 44 | 7.7 | 7 | pembrolizumab 200 mg q3w | 15.7 | false | MSS | 2026-03-15T05:35:59.307323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969875 | REC_0009903 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 13.6 | 71 | female | 1 | 9 | 4.2 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:59.307569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438021 | REC_0009904 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 14 | 14.2 | 63 | female | 0 | 19 | 7 | 5 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:59.307833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735998 | REC_0009905 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 6.6 | 78 | female | 1 | 21 | 6 | 7 | entrectinib 600 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:59.308208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717318 | REC_0009906 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 6.8 | 64 | female | 1 | 8 | 4.2 | 4 | sotorasib 960 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.308548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582672 | REC_0009907 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.7 | 74 | male | 0 | 7 | 6.5 | 7 | sotorasib 960 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:59.309005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150204 | REC_0009908 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 4.9 | 76 | female | 2 | 12 | 5.8 | 1 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:35:59.309332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787364 | REC_0009909 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.3 | 78 | female | 1 | 14 | 5.7 | 6 | entrectinib 600 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:35:59.309645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971525 | REC_0009910 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8.5 | 85 | female | 1 | 8 | 4 | 6 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.309935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202728 | REC_0009911 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.8 | 74 | female | 2 | 6 | 6.2 | 8 | sotorasib 960 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:59.310179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761205 | REC_0009912 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.7 | 70 | male | 2 | 17 | 5.9 | 2 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:59.310422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488393 | REC_0009913 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 7.2 | 53 | male | 0 | 14 | 5 | 6 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:59.310656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304936 | REC_0009914 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 11.7 | 59 | male | 1 | 9 | 5.4 | 0 | sotorasib 960 mg daily | 30.5 | true | MSS | 2026-03-15T05:35:59.310893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103418 | REC_0009915 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 17.6 | 75 | female | 1 | 11 | 5.2 | 6 | osimertinib 80 mg daily | 20.3 | false | MSI-H | 2026-03-15T05:35:59.311140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460206 | REC_0009916 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 5.1 | 75 | female | 1 | 15 | 7.4 | 1 | sotorasib 960 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:59.311387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358453 | REC_0009917 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.1 | 60 | female | 0 | 41 | 3.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:35:59.311652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587482 | REC_0009918 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 9.9 | 61 | female | 0 | 13 | 4.5 | 7 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:59.311926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666676 | REC_0009919 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.5 | 69 | male | 0 | 17 | 5.1 | 1 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:59.312270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400341 | REC_0009920 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 6.4 | 66 | male | 0 | 44 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.8 | true | MSS | 2026-03-15T05:35:59.312664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110948 | REC_0009921 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 8.8 | 72 | female | 1 | 16 | 4.7 | 5 | entrectinib 600 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:59.312908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249427 | REC_0009922 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.1 | 74 | female | 2 | 59 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.3 | true | MSS | 2026-03-15T05:35:59.313144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804770 | REC_0009923 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.7 | 58 | male | 1 | 17 | 4 | 7 | alectinib 600 mg BID | 16.1 | true | MSS | 2026-03-15T05:35:59.313380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114414 | REC_0009924 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 6.6 | 70 | female | 1 | 19 | 7 | 5 | osimertinib 80 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:59.313610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717073 | REC_0009925 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.2 | 66 | male | 1 | 15 | 7.7 | 7 | osimertinib 80 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:59.313843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159837 | REC_0009926 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.9 | 68 | female | 1 | 20 | 5.8 | 8 | alectinib 600 mg BID | 7.8 | false | MSI-H | 2026-03-15T05:35:59.314073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824390 | REC_0009927 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 15.5 | 67 | female | 0 | 21 | 4.5 | 4 | alectinib 600 mg BID | 11.6 | false | MSI-H | 2026-03-15T05:35:59.314321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521643 | REC_0009928 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.2 | 83 | female | 1 | 34 | 5.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:35:59.314558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390476 | REC_0009929 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 10.6 | 73 | female | 1 | 28 | 5.7 | 2 | pembrolizumab 200 mg q3w | 33.2 | true | MSI-H | 2026-03-15T05:35:59.314818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724142 | REC_0009930 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.6 | 56 | female | 1 | 60 | 4.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.6 | true | MSS | 2026-03-15T05:35:59.315068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702139 | REC_0009931 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.4 | 72 | female | 2 | 26 | 6 | 6 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.315312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848583 | REC_0009932 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.2 | 66 | female | 0 | 40 | 7.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.8 | true | MSS | 2026-03-15T05:35:59.315554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395360 | REC_0009933 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 14.2 | 78 | female | 1 | 4 | 4.9 | 2 | osimertinib 80 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:59.315942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951408 | REC_0009934 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.4 | 61 | male | 0 | 8 | 6.2 | 5 | alectinib 600 mg BID | 13.9 | false | MSS | 2026-03-15T05:35:59.316271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853592 | REC_0009935 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.7 | 54 | female | 0 | 23 | 5.2 | 2 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:59.316532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139017 | REC_0009936 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 12.8 | 80 | female | 2 | 19 | 4.8 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:59.316779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195826 | REC_0009937 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 11.6 | 69 | female | 0 | 16 | 3.7 | 2 | entrectinib 600 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:59.317016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517782 | REC_0009938 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.8 | 57 | male | 1 | 11 | 7.7 | 7 | entrectinib 600 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:59.317256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214580 | REC_0009939 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 12.3 | 65 | female | 0 | 7 | 6.6 | 4 | osimertinib 80 mg daily | 16.7 | true | MSS | 2026-03-15T05:35:59.317511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161754 | REC_0009940 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.7 | 66 | female | 1 | 38 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:35:59.317758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320851 | REC_0009941 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 9.7 | 82 | male | 3 | 7 | 5.8 | 5 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:35:59.318023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180308 | REC_0009942 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 12.5 | 78 | female | 1 | 16 | 3.8 | 0 | entrectinib 600 mg daily | 25.7 | true | MSI-H | 2026-03-15T05:35:59.318279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732952 | REC_0009943 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 9.9 | 69 | female | 1 | 8 | 4.5 | 3 | entrectinib 600 mg daily | 22.3 | true | MSS | 2026-03-15T05:35:59.318536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310639 | REC_0009944 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 11.2 | 66 | female | 1 | 0 | 5.2 | 2 | osimertinib 80 mg daily | 16.7 | true | MSI-H | 2026-03-15T05:35:59.318791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458079 | REC_0009945 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 17.2 | 77 | female | 1 | 17 | 5 | 3 | sotorasib 960 mg daily | 6 | true | MSI-H | 2026-03-15T05:35:59.319043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369684 | REC_0009946 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 12.6 | 65 | male | 1 | 11 | 5.3 | 7 | osimertinib 80 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:35:59.319404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195078 | REC_0009947 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 16.1 | 79 | male | 0 | 18 | 7.5 | 1 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:59.319656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981421 | REC_0009948 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 13.4 | 63 | male | 1 | 15 | 4 | 5 | sotorasib 960 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:59.319894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286003 | REC_0009949 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 11.1 | 57 | male | 1 | 15 | 5.7 | 2 | osimertinib 80 mg daily | 24.9 | true | MSI-H | 2026-03-15T05:35:59.320296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721350 | REC_0009950 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 8 | 60 | female | 0 | 11 | 6.5 | 1 | entrectinib 600 mg daily | 20.9 | false | MSS | 2026-03-15T05:35:59.320563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448079 | REC_0009951 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10 | 81 | female | 3 | 18 | 4.2 | 5 | osimertinib 80 mg daily | 4.8 | false | MSI-H | 2026-03-15T05:35:59.320815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788766 | REC_0009952 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 17.2 | 62 | female | 1 | 4 | 6.3 | 3 | sotorasib 960 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:59.321059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885553 | REC_0009953 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 15 | 71 | female | 0 | 14 | 5.5 | 5 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.321300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574263 | REC_0009954 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 10.9 | 69 | female | 0 | 7 | 6.7 | 0 | entrectinib 600 mg daily | 32.8 | false | MSS | 2026-03-15T05:35:59.321538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602092 | REC_0009955 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.5 | 77 | female | 3 | 57 | 4.3 | 2 | pembrolizumab 200 mg q3w | 16.9 | true | MSS | 2026-03-15T05:35:59.321779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838721 | REC_0009956 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 15.5 | 70 | female | 2 | 23 | 4.8 | 6 | sotorasib 960 mg daily | 7.6 | false | MSI-H | 2026-03-15T05:35:59.322027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137932 | REC_0009957 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 10.7 | 52 | male | 0 | 17 | 4.2 | 1 | osimertinib 80 mg daily | 23.2 | false | MSS | 2026-03-15T05:35:59.322279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119009 | REC_0009958 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 11.6 | 71 | female | 2 | 18 | 4.4 | 1 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:59.322532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468876 | REC_0009959 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 3.9 | 60 | male | 1 | 53 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.1 | true | MSS | 2026-03-15T05:35:59.322902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174426 | REC_0009960 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 6.4 | 90 | female | 2 | 15 | 4.9 | 3 | alectinib 600 mg BID | 12.6 | false | MSS | 2026-03-15T05:35:59.323164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599876 | REC_0009961 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 12 | 81 | female | 2 | 16 | 3.9 | 6 | sotorasib 960 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.323423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659821 | REC_0009962 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.1 | 66 | female | 1 | 15 | 5.7 | 7 | osimertinib 80 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:59.323673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492820 | REC_0009963 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.3 | 64 | female | 0 | 8 | 6.5 | 6 | alectinib 600 mg BID | 11.8 | true | MSS | 2026-03-15T05:35:59.323923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862095 | REC_0009964 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.9 | 65 | female | 0 | 38 | 5.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:59.324222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356318 | REC_0009965 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 34 | 15.1 | 60 | male | 1 | 24 | 5.3 | 8 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:59.324508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304992 | REC_0009966 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.7 | 71 | female | 1 | 36 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:35:59.324767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754670 | REC_0009967 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 17.9 | 55 | male | 0 | 13 | 6.3 | 7 | pembrolizumab 200 mg q3w | 11.9 | true | MSI-H | 2026-03-15T05:35:59.325027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266596 | REC_0009968 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 9.4 | 55 | male | 1 | 18 | 4.8 | 7 | sotorasib 960 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:59.325278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166227 | REC_0009969 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 19.4 | 69 | female | 0 | 26 | 5.5 | 1 | osimertinib 80 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:59.325525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814648 | REC_0009970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 18.8 | 73 | female | 1 | 13 | 4.4 | 1 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:59.325775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200708 | REC_0009971 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 8.9 | 71 | male | 1 | 7 | 4.5 | 1 | pembrolizumab 200 mg q3w | 20.1 | true | MSS | 2026-03-15T05:35:59.326018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699388 | REC_0009972 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.6 | 60 | female | 1 | 11 | 6.3 | 8 | sotorasib 960 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:35:59.326389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841173 | REC_0009973 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.8 | 67 | female | 0 | 21 | 6.1 | 3 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:59.326660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149388 | REC_0009974 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 10.2 | 65 | male | 1 | 22 | 3.9 | 2 | alectinib 600 mg BID | 8.3 | false | MSS | 2026-03-15T05:35:59.326921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482463 | REC_0009975 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 10.9 | 59 | male | 1 | 38 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.9 | false | MSI-H | 2026-03-15T05:35:59.327181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462605 | REC_0009976 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.3 | 74 | female | 2 | 27 | 4.5 | 3 | pembrolizumab 200 mg q3w | 8.2 | false | MSS | 2026-03-15T05:35:59.327428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861175 | REC_0009977 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13.8 | 59 | female | 1 | 13 | 4.2 | 6 | sotorasib 960 mg daily | 14 | false | MSS | 2026-03-15T05:35:59.327683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271829 | REC_0009978 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.7 | 62 | female | 1 | 58 | 7.1 | 4 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:59.327931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281966 | REC_0009979 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 12.6 | 81 | female | 1 | 19 | 5.1 | 1 | alectinib 600 mg BID | 14.1 | false | MSI-H | 2026-03-15T05:35:59.328235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450118 | REC_0009980 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 12.1 | 65 | female | 0 | 20 | 2 | 5 | osimertinib 80 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:35:59.328513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616592 | REC_0009981 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 5.7 | 69 | male | 1 | 8 | 7 | 3 | entrectinib 600 mg daily | 12 | true | MSS | 2026-03-15T05:35:59.328764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224650 | REC_0009982 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.4 | 68 | female | 0 | 11 | 6.3 | 3 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:35:59.329007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348806 | REC_0009983 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.7 | 65 | male | 0 | 11 | 5.7 | 5 | entrectinib 600 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:35:59.329265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104970 | REC_0009984 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 10.3 | 62 | male | 0 | 17 | 5.1 | 0 | osimertinib 80 mg daily | 40.4 | false | MSS | 2026-03-15T05:35:59.329519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616556 | REC_0009985 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.3 | 64 | male | 1 | 13 | 5.8 | 1 | sotorasib 960 mg daily | 24.1 | true | MSS | 2026-03-15T05:35:59.329897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322912 | REC_0009986 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.9 | 67 | female | 0 | 13 | 6.3 | 5 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:59.330160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189030 | REC_0009987 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 13.9 | 60 | female | 0 | 24 | 4.9 | 0 | osimertinib 80 mg daily | 63.2 | true | MSS | 2026-03-15T05:35:59.330418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877715 | REC_0009988 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 11.5 | 77 | female | 1 | 16 | 6.3 | 6 | alectinib 600 mg BID | 11.3 | false | MSI-H | 2026-03-15T05:35:59.330661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993056 | REC_0009989 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.2 | 72 | female | 2 | 15 | 7.6 | 6 | sotorasib 960 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:59.330897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622853 | REC_0009990 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.5 | 61 | female | 0 | 10 | 5 | 6 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:59.331134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157697 | REC_0009991 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.3 | 62 | female | 1 | 10 | 7 | 7 | sotorasib 960 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:59.331371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969869 | REC_0009992 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.3 | 68 | female | 0 | 24 | 5 | 6 | pembrolizumab 200 mg q3w | 21.6 | false | MSS | 2026-03-15T05:35:59.331603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215791 | REC_0009993 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 14.9 | 76 | female | 1 | 16 | 4.8 | 5 | pembrolizumab 200 mg q3w | 8.7 | false | MSI-H | 2026-03-15T05:35:59.331839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664926 | REC_0009994 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 6.5 | 74 | male | 2 | 13 | 4.9 | 7 | entrectinib 600 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:59.332145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881347 | REC_0009995 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 5.8 | 68 | female | 0 | 16 | 4 | 4 | sotorasib 960 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:59.332430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249632 | REC_0009996 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 15.4 | 75 | female | 3 | 16 | 5 | 1 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:59.332699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233337 | REC_0009997 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 13.9 | 69 | female | 0 | 8 | 4.8 | 1 | osimertinib 80 mg daily | 26.3 | true | MSI-H | 2026-03-15T05:35:59.332962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515506 | REC_0009998 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 6.7 | 75 | female | 2 | 11 | 6.2 | 2 | osimertinib 80 mg daily | 8.5 | true | MSS | 2026-03-15T05:35:59.333348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651017 | REC_0009999 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 9.3 | 67 | female | 1 | 8 | 4.6 | 4 | sotorasib 960 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:59.333644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860977 | REC_0010000 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 17.2 | 61 | female | 0 | 12 | 4.3 | 5 | entrectinib 600 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:59.333921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.